The findings of a recent study, which will appear in Cancer Cell this
month, provide a clue to the mystery of multiple myeloma cancer cells’
resistance to powerful drugs. A specific type of immune system cell is
literally “switching teams” and protecting the cancer cells instead of
destroying them ...
“Importantly, our study provides a therapeutic remedy for correcting
this defect,” Chauhan added. A drug known as cytosine phosphate guanine
oligodeoxynucleotides (CpG ODNs) combats this problem by attaching to
receptors on the surface of pDC cells. This triggers the pDCs to return
to their normal status as immune system cells.
Full article: http://www.myelomabeacon.com/news/2009/10/07/immune-system-c
Regards,
Craig